| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF00268938 |
| P698 | PubMed publication ID | 8307781 |
| P50 | author | Theodorus H Van der Kwast | Q56959613 |
| P2093 | author name string | F H Schröder | |
| P J Janssen | |||
| J A Ruizeveld de Winter | |||
| H van Krimpen | |||
| J L Krijnen | |||
| P2860 | cites work | Neuroendocrine differentiation in human prostatic carcinoma | Q35226787 |
| Prostatic adenocarcinoma evolving into carcinoid: selective effect of hormonal treatment? | Q39571663 | ||
| Multidirectional differentiation in neuroendocrine neoplasms | Q40094808 | ||
| The influence of hormonal therapy on survival of men with advanced prostatic cancer. | Q41457056 | ||
| Dopaminergic and Ligand-Independent Activation of Steroid Hormone Receptors | Q41653040 | ||
| Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates | Q42466077 | ||
| Androgen receptor expression in human tissues: an immunohistochemical study | Q42471568 | ||
| Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study | Q43900936 | ||
| Characterization of monoclonal antibodies raised against the prostatic cancer cell line PC-82. | Q45279812 | ||
| Androgen receptors in biopsy specimens of prostate adenocarcinoma. Heterogeneity of distribution and relation to prognostic significance of receptor measurements for survival of advanced cancer patients. | Q52592256 | ||
| Androgen receptors in endocrine-therapy-resistant human prostate cancer. | Q54296309 | ||
| Epitope prediction and confirmation for the human androgen receptor: Generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy | Q63966415 | ||
| Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry | Q63966418 | ||
| Prostatic carcinoma: histological and immunohistological factors affecting prognosis | Q68578366 | ||
| Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases | Q68984988 | ||
| The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker" | Q69794650 | ||
| Xenografted small cell undifferentiated cancer of prostate: possible common origin with prostatic adenocarcinoma | Q69812760 | ||
| Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases | Q70169490 | ||
| The histogenesis of small cell carcinoma of the prostate an immunohistochemical study | Q70200897 | ||
| The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue | Q70679701 | ||
| Correlation between clinical response to antiandrogenic therapy and occurrence of receptors in human prostatic cancer | Q72619123 | ||
| Steroid receptors and hormone responsiveness of human prostatic carcinoma | Q72770369 | ||
| P433 | issue | 5 | |
| P921 | main subject | prostate cancer | Q181257 |
| medical laboratory technology | Q28119945 | ||
| P304 | page(s) | 393-398 | |
| P577 | publication date | 1993-11-01 | |
| P1433 | published in | Histochemistry | Q25532912 |
| P1476 | title | Do neuroendocrine cells in human prostate cancer express androgen receptor? | |
| P478 | volume | 100 |
| Q71869783 | Absence of serum prostate-specific antigen and loss of tissue immunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy: a report of two cases |
| Q42520039 | Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate |
| Q40915126 | Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines |
| Q40605826 | Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells |
| Q71085216 | Calcitonin receptor mRNA expression in the human prostate |
| Q36796375 | Cancer stem cells and tumor transdifferentiation: implications for novel therapeutic strategies |
| Q73911301 | Circulating neuroendocrine markers in patients with prostate carcinoma |
| Q36639877 | Clinical implications of neuroendocrine differentiation in prostate cancer |
| Q39203734 | Distribution of Neuroendocrine Cells in the Transition Zone of the Prostate |
| Q44803724 | Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma |
| Q24791371 | Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage |
| Q34099383 | GABA's control of stem and cancer cell proliferation in adult neural and peripheral niches |
| Q24669799 | Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model |
| Q44124134 | Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival |
| Q52714356 | MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells. |
| Q35217386 | Models of metastatic prostate cancer: a transgenic perspective |
| Q34491450 | Molecular action of androgen in the normal and neoplastic prostate |
| Q40291858 | Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells |
| Q30837415 | Neuroendocrine Cells of the Prostate Derive from the Neural Crest. |
| Q40519386 | Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. |
| Q74607832 | Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects |
| Q58327426 | Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer |
| Q35782075 | Neuroendocrine differentiation in human prostatic tumor models |
| Q36537698 | Neuroendocrine differentiation in prostate cancer |
| Q74544937 | Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment |
| Q71710579 | Neuroendocrine peptides in the prostate |
| Q49347811 | Neuroendocrine tumors of the prostate |
| Q40815476 | Neurogenic origin of human prostate endocrine cells |
| Q53249505 | New approaches to the treatment of advanced prostate cancer. |
| Q77935946 | Pre- and postnatal testosterone administration induces proliferative epithelial lesions with neuroendocrine differentiation in the dorsal lobe of the rat prostate |
| Q34126555 | Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells |
| Q88955636 | Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer |
| Q50997644 | Sex steroid receptor expression in 'carcinoid' tumours of the breast. |
| Q36024996 | Somatostatin receptors and their interest in diagnostic pathology |
| Q89998761 | The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells |
| Q35131420 | The diffuse endocrine system: from embryogenesis to carcinogenesis. |
| Q37137946 | The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. |
| Q26795611 | Therapy escape mechanisms in the malignant prostate |
| Q73317172 | Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate |
| Q35166475 | Utility of FDG-PET in clinical neuroendocrine prostate cancer |
| Q39999738 | Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells |
| Q46022237 | Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT. |
Search more.